Literature DB >> 17011456

The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage.

Keiichi Jingu1, Tomohiro Kaneta, Kenji Nemoto, Azusa Ichinose, Minako Oikawa, Yoshihiro Takai, Yoshihiro Ogawa, Eiko Nakata, Toru Sakayauchi, Kenji Takai, Toshiyuki Sugawara, Kakutaro Narazaki, Hiroshi Fukuda, Shoki Takahashi, Shogo Yamada.   

Abstract

PURPOSE: We evaluated the clinical significance of focal increased uptake in the basal myocardium on F-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with esophageal cancer after radiotherapy. METHODS AND MATERIALS: Between August 2004 and July 2005, a total of 64 patients who had been irradiated for thoracic esophageal cancer underwent FDG-PET at least three months after the completion of chemoradiotherapy. Some patients showed increased FDG uptake in the basal portion of the myocardium. To clarify the clinical significance of these findings, further examinations of hearts were performed. The dose distribution in the myocardium with high FDG uptake was also analyzed retrospectively.
RESULTS: Thirteen (20.3%) of the 64 patients showed high FDG uptake in the basal myocardium corresponding to the irradiated fields compared with FDG uptake in the myocardium outside the irradiated fields. Eight of the 13 patients consented to undergo examinations of the heart. Five of those eight patients showed low 123I-BMIPP uptake and four showed low 201TlCl uptake in the myocardium corresponding with high FDG uptake regions. In two patients, delayed enhancement was found in some parts of the area with high FDG uptake on Gd-DTPA magnetic resonance imaging (MRI), and the delay-enhanced lesion showed hypokinesia on cine-MRI in one patient.
CONCLUSIONS: FDG-PET often shows focal increased uptake in the basal myocardium after radiotherapy for esophageal cancer. This finding indicates the possibility of radiation-induced cardiac damage, and cardiac function and symptoms of such patients should be followed carefully.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011456     DOI: 10.1016/j.ijrobp.2006.06.007

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

Review 2.  How early? ASAP: molecular and functional imaging!

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

3.  Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer.

Authors:  Yevgeniy Vinogradskiy; Quentin Diot; Bernard Jones; Richard Castillo; Edward Castillo; Jennifer Kwak; Daniel Bowles; Inga Grills; Nicholas Myziuk; Thomas Guerrero; Craig Stevens; Tracey Schefter; Laurie E Gaspar; Brian Kavanagh; Moyed Miften; Chad Rusthoven
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-01-23       Impact factor: 7.038

4.  Radiation-induced myocardial damage indicated by focal defect on 123I-MIBG SPECT.

Authors:  Takashi Norikane; Yuka Yamamoto; Yasukage Takami; Katsuya Mitamura; Hanae Arai-Okuda; Ryosuke Tani; Yoshihiro Nishiyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-15       Impact factor: 9.236

5.  Pitfalls in radiation oncology. "Myocardial metastasis" in PET-CT after palliative radiation treatment of the left 5th rib.

Authors:  P Kröpil; W Budach; E Bölke; P A Gerber; F Zinnmann; H Hautzel; G Antoch; A Scherer; C Matuschek
Journal:  Strahlenther Onkol       Date:  2012-02-22       Impact factor: 3.621

6.  Trastuzumab aggravates radiation induced cardiotoxicity in mice.

Authors:  Peiqiang Yi; Huan Li; Jun Su; Jialin Cai; Cheng Xu; Jiayi Chen; Lu Cao; Min Li
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

7.  Posttreatment FDG-PET uptake in the supraglottic and glottic larynx correlates with decreased quality of life after chemoradiotherapy.

Authors:  Ken Dornfeld; Shane Hopkins; Joel Simmons; Douglas R Spitz; Yusuf Menda; Michael Graham; Russell Smith; Gerry Funk; Lucy Karnell; Michael Karnell; Maude Dornfeld; Min Yao; John Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

8.  A case report and review of the literature: cardiotoxicities after radiotherapy for breast cancer patients with high-risk factors of cardiovascular disease.

Authors:  Liuwei Tang; Haruo Matsushita; Yojiro Ishikawa; Takanori Ishida; Keiichi Jingu
Journal:  Int Cancer Conf J       Date:  2019-10-08

Review 9.  Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT.

Authors:  Ryogo Minamimoto
Journal:  Jpn J Radiol       Date:  2021-01-31       Impact factor: 2.374

Review 10.  Risk Management for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) and Taiwan Society of Cardiology (TSOC).

Authors:  Long-Sheng Lu; Yen-Wen Wu; Joseph Tung-Chieh Chang; Wei-Ting Chang; Ting-Hsing Chao; Helen Hai-Wen Chen; Yu-Jen Chen; Kai-Hung Cheng; Wen-Lin Hsu; Chung-Lieh Hung; Sung-Hsin Kuo; Ji-An Liang; Hung-Ju Lin; Ping-Yen Liu; Wen-Shan Liu; Yen-Wen Liu; Pei-Wei Shueng; Chao-Yung Wang; Charles Jia-Yin Hou; Jeng-Fong Chiou
Journal:  Acta Cardiol Sin       Date:  2022-01       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.